Relapsed and refractory aggressive NHL: Time for a change

被引：15

作者：

Gangatharan, Shane ^{[1
]}

Kuruvilla, John ^{[1
,2
]}

机构：

[1] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada

[2] Univ Toronto, Dept Med, Toronto, ON, Canada

来源：

TRANSFUSION AND APHERESIS SCIENCE | 2013年 / 49卷 / 01期

关键词：

B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; PHASE-II TRIAL; HUMANIZED ANTI-CD22 ANTIBODY; PERIPHERAL T-CELL; AUTOLOGOUS TRANSPLANTATION; CONDITIONING REGIMENS; SALVAGE CHEMOTHERAPY; BRENTUXIMAB VEDOTIN; NONGERMINAL CENTER;

D O I：

10.1016/j.transci.2013.05.029

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Despite improvements in treatment for aggressive non-Hodgkin lymphoma (NHL), the outcomes for patients with relapsed or refractory B- or T-cell NHL after primary therapy remain poor. While some patients may be cured by the standard of care of salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), this treatment is unsuitable for the majority. Advances in disease biology and novel therapies have created uncertainty as to the role of old standards and opportunities to develop new rationally developed treatment options. We will review the standard approaches in this disease area and highlight areas that merit further study. (C) 2013 Published by Elsevier Ltd.

引用

页码：72 / 79

页数：8

共 66 条

[1]

Abouyabis Abeer N, 2011, ISRN Hematol, V2011, P623924, DOI 10.5402/2011/623924

[2] Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study [J].

Advani, Anjali ;

Coiffier, Bertrand ;

Czuczman, Myron S. ;

Dreyling, Martin ;

Foran, James ;

Gine, Eva ;

Gisselbrecht, Christian ;

Ketterer, Nicolas ;

Nasta, Sunita ;

Rohatiner, Ama ;

Schmidt-Wolf, Ingo G. H. ;

Schuler, Martin ;

Sierra, Jorge ;

Smith, Mitchell R. ;

Verhoef, Gregor ;

Winter, Jane N. ;

Boni, Joseph ;

Vandendries, Erik ;

Shapiro, Mark ;

Fayad, Luis .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2085-2093

[3]

Advani RH, 2012, J CLIN ONCOL

[4] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[5]

Armitage James O, 2010, Clin Adv Hematol Oncol, V8, P1

[6] Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab [J].

Barrans, Sharon ;

Crouch, Simon ;

Smith, Alex ;

Turner, Kathryn ;

Owen, Roger ;

Patmore, Russell ;

Roman, Eve ;

Jack, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3360-3365

[7] Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks? [J].

Barton, Sarah ;

Hawkes, Eliza A. ;

Wotherspoon, Andrew ;

Cunningham, David .

ONCOLOGIST, 2012, 17 (12) :1562-1573

[8]

Blay JY, 1998, BLOOD, V92, P3562

[9] Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab [J].

Carnahan, Josette ;

Stein, Rhona ;

Qu, Zhengxing ;

Hess, Kristen ;

Cesano, Alessandra ;

Hansen, Hans J. ;

Goldenberg, David M. .

MOLECULAR IMMUNOLOGY, 2007, 44 (06) :1331-1341

[10] CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies [J].

Castillo, Jorge J. ;

Furman, Michael ;

Winer, Eric S. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (01) :15-22

← 1 2 3 4 5 6 7 →